Impact Therapeutics is focused on developing innovative cancer treatments based on the concept of synthetic lethality, which targets cancer cells' unique vulnerabilities. The company has established a robust pipeline centered around DNA damage repair (DDR) pathways, creating one of the most comprehensive DDR product portfolios in the global biopharmaceutical industry. Their lead product, Senaparib (IMP4297), is a PARP inhibitor that has shown promising results in clinical trials for various cancers, including ovarian and small cell lung cancer. Additionally, the company is advancing other candidates such as the Wee1 inhibitor (IMP7068) and ATR inhibitor (IMP9064), which are currently in various stages of clinical research.

The synthetic lethality approach allows for the selective targeting of cancer cells with specific genetic mutations, making it a potential solution for overcoming treatment resistance commonly seen with traditional therapies. Impact Therapeutics is also exploring new synthetic lethality targets and is open to strategic collaborations to maximize the clinical and commercial potential of its drug candidates. Their commitment to research and development, combined with a strong management team and partnerships, positions them as a key player in the fight against cancer.

Impact Therapeutics

Company Details